Novo Nordisk CEO's pay sets itself apart on especially one point

German investment bank Berenberg has compared the salaries of a range of top execs in the pharmaceutical industry, and in opposition to everyone else, Lars Fruergaard Jørgensen's bonus scheme is not tied to the company share price.

Novo Nordisk President & CEO | Photo: Stine Bidstrup/ERH

The bonus scheme of Novo Nordisk CEO and President Lars Fruergaard Jørgensen is not tied in with the share price of the Danish pharmaceutical company, which comes as a surprise to German investment bank Berenberg.

The bank has analyzed the salaries of CEOs in 12 of the world's largest pharmaceutical companies, and Fruergaard Jørgensen's bonus scheme is the only one that does not correlate with the development of the share price of his company.

Read the whole article

Get 14 days free access.
No credit card required.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Pfizer upgrades guidance for sales of covid-19 vaccine

The US pharmaceutical company Pfizer now predicts sales of its coronavirus vaccines will total USD 33.5bn this year. The previous estimate was UDS 26bn. Meanwhile, the company has revealed the guidance for its annual revenue.

Further reading

Trial banner

Latest news

See all jobs